Rising count in cases of chronic myeloid leukemia disease, is anticipated to fuel the global chronic myeloid leukemia treatment market growth in the forecast period. For example, in 2020, as per NCBI, the data about chronic myeloid leukemia, was gathered from global burden, and it states that the chronic myeloid leukemia cases differ with age, gender, and regions. Furthermore, the yearly cases of CML differs from 0.4/100,000 people to 1.75/100,000 people in various regions. The cases of CML rises with age and is intermittent in children below 14 years of age.
Moreover, non-official and official regulatory to raise perception about tumor and cancer therapy is projected to fuel the development of market. For example, UICC, a non-official organization involved in decreasing the global cancer cases and to enhance perception about the cancer
The coronavirus pandemic was first seen on December 31, 2019 in Wuhan, China. The World Health Organization stated the COVID-19 an epidemic on March 11, 2020. The epidemic led to interruptions in performing medical trials. This led to halt in goods authorization and hence hampered the market development. The COVID-19 pandemic has also impacted the economy by straightly impacting the manufacture and need, making interruptions in supply channels, and creating an adverse economic effect on organizations and financial markets.
Rise in occurrence of chronic myeloid leukemia fuels the need for CML therapy products. Hence, key players are involved in growing new goods. This is further to fuel the development of market. For example, the U.S. FDA granted the supplementary novel drug application for ponatinib to cure patients with chronic-phase chronic myeloid leukemia in December 2020.
The global chronic myeloid leukemia treatment market is projected to show a CAGR of 6.0% over the predicted duration. Robust pipeline for chronic leukemia treatment items is expected to fuel the development of market. For example, a medical test survey sponsored by Novartis Pharmaceuticals for drug: ABL001 is in clinical trial phase III.
Based on drug type, the tyrosine kinase inhibitors sector is anticipated to show the huge CAGR in the global chronic myeloid leukemia treatment market during the predicted duration. This sector is next divided into nilotinib (tasigna), imatinib (gleevec), dasatinib (sprycel), ponatinib (iclusig), bosutinib (bosulif), asciminib (scemblix), and others. The accessibility of U.S. FDA approved TKIs products for therapy of chronic myeloid leukemia is projected to fuel the development of segment. For example, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and amidst others are the producers involved in providing TKIs products for CML.
Among distribution channels, hospital pharmacies segment is anticipated to record the high CAGR over the predicted duration in the global chronic myeloid leukemia treatment market, as the mainstream of chronic myeloid leukemia drugs are vended by hospital pharmacies.
✔️Request for customization in Report:
Among region, Asia Pacific is expected to increase at the huge CAGR in the global chronic myeloid leukemia treatment market during the predicted duration. Potential aim of key players on development plans such as partnership, acquirement, product launch & approval, and others in the Asia Pacific region is anticipated to fuel the market growth. For example, in April 2020, Dr. Reddy’s Laboratories Ltd., a pharmaceutical company, declared the approval of Invista, a formulation of Dasatinib that is bioequivalent to the innovator brand. Furthermore, it is shown for the therapy of chronic boosted or myeloid or lymphoid blast phase and afresh examination in chronic phase adult patients with chronic myeloid leukemia in India.
Key players involved in the global chronic myeloid leukemia treatment market are Teva Pharmaceutical Industries Ltd, Innovent Biologics, Inc., Lupin, Viatris Inc. (Mylan N.V.),F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Million Health Pharmaceuticals, Novartis AG, Pfizer Inc., IL-YANG PHARM CO. LTD., and Celon Labs
• Analysts place significant emphasis on mega-trends that drive consumer choice and will provide a clearer picture of future opportunities that can be explored across sectors, resulting in increased revenue.
Coherent Market Insights is a global market intelligence and consulting firm that offers syndicated and customised research reports as well as consulting services. We’re known for our actionable insights and reliable reports in a wide range of industries, including aerospace and defence, agriculture, food and beverage, automotive, chemicals and materials, and virtually every other domain and sub-domain imaginable. Our clients benefit from our highly reliable and accurate reports. We’re also committed to continuing to provide measurable, long-term results for our clients after COVID-19 by playing a leading role in providing insights into various sectors.
1001 4th Ave, #3200 Seattle,
WA 98154, USA
United States of America: 📞+1-206-701-6702
United Kingdom: 📞+44-020-8133-4027